James W Vardiman

Summary

Affiliation: University of Chicago
Country: USA

Publications

  1. ncbi request reprint Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary
    John M Bennett
    Blood 99:3074-5. 2002
  2. ncbi request reprint Myelodysplastic/myeloproliferative neoplasms
    Elizabeth Hyjek
    Department of Pathology, Hematopathology Section, University of Chicago, Chicago, Illinois, USA
    Semin Diagn Pathol 28:283-97. 2011
  3. ncbi request reprint The World Health Organization (WHO) classification of the myeloid neoplasms
    James W Vardiman
    Department of Pathology, University of Chicago, IL 60637, USA
    Blood 100:2292-302. 2002
  4. doi request reprint The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    James W Vardiman
    Department of Pathology, University of Chicago, IL, USA
    Blood 114:937-51. 2009
  5. doi request reprint Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802
    Wendy Stock
    University of Chicago, Illinois, USA
    Cancer 119:90-8. 2013
  6. doi request reprint The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms
    James W Vardiman
    University of Chicago Medical Center, 5841 South Maryland Avenue, MC0008, Chicago, IL 60637, United States
    Chem Biol Interact 184:16-20. 2010
  7. ncbi request reprint Myelodysplastic/myeloproliferative diseases
    James W Vardiman
    University of Chicago, Department of Pathology, Chicago, Illinois, USA
    Cancer Treat Res 121:13-43. 2004
  8. pmc What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
    Wendy Stock
    Section of Hematology Oncology, Department of Medicine, University of Chicago and University of Chicago Cancer Research Center, IL 60637, USA
    Blood 112:1646-54. 2008
  9. ncbi request reprint Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant
    Zeba N Singh
    Section of Hematopathology, Department of Pathology, University of Chicago, Chicago, IL 60637, USA
    Am J Clin Pathol 127:197-205. 2007
  10. ncbi request reprint The new World Health Organization classification of myeloid neoplasms: Q&A with James W. Vardiman, MD
    James W Vardiman
    Department of Pathology, University of Chicago, Illinois, USA
    Clin Adv Hematol Oncol 1:18, 21. 2003

Collaborators

Detail Information

Publications16

  1. ncbi request reprint Myelodysplastic syndromes: from French-American-British to World Health Organization: a commentary
    John M Bennett
    Blood 99:3074-5. 2002
  2. ncbi request reprint Myelodysplastic/myeloproliferative neoplasms
    Elizabeth Hyjek
    Department of Pathology, Hematopathology Section, University of Chicago, Chicago, Illinois, USA
    Semin Diagn Pathol 28:283-97. 2011
    ..In this review we will give an overview of these neoplasms and focus on adult MDS/MPN, especially CMML. We will give only brief updates for aCML and RARS-T; JMML will be discussed in a separate article...
  3. ncbi request reprint The World Health Organization (WHO) classification of the myeloid neoplasms
    James W Vardiman
    Department of Pathology, University of Chicago, IL 60637, USA
    Blood 100:2292-302. 2002
    ....
  4. doi request reprint The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
    James W Vardiman
    Department of Pathology, University of Chicago, IL, USA
    Blood 114:937-51. 2009
    ....
  5. doi request reprint Dose intensification of daunorubicin and cytarabine during treatment of adult acute lymphoblastic leukemia: results of Cancer and Leukemia Group B Study 19802
    Wendy Stock
    University of Chicago, Illinois, USA
    Cancer 119:90-8. 2013
    ....
  6. doi request reprint The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms
    James W Vardiman
    University of Chicago Medical Center, 5841 South Maryland Avenue, MC0008, Chicago, IL 60637, United States
    Chem Biol Interact 184:16-20. 2010
    ....
  7. ncbi request reprint Myelodysplastic/myeloproliferative diseases
    James W Vardiman
    University of Chicago, Department of Pathology, Chicago, Illinois, USA
    Cancer Treat Res 121:13-43. 2004
  8. pmc What determines the outcomes for adolescents and young adults with acute lymphoblastic leukemia treated on cooperative group protocols? A comparison of Children's Cancer Group and Cancer and Leukemia Group B studies
    Wendy Stock
    Section of Hematology Oncology, Department of Medicine, University of Chicago and University of Chicago Cancer Research Center, IL 60637, USA
    Blood 112:1646-54. 2008
    ..Based on these observations, a prospective study for AYAs with ALL using the more successful approach of the CCG has been initiated...
  9. ncbi request reprint Therapy-related myelodysplastic syndrome: morphologic subclassification may not be clinically relevant
    Zeba N Singh
    Section of Hematopathology, Department of Pathology, University of Chicago, Chicago, IL 60637, USA
    Am J Clin Pathol 127:197-205. 2007
    ..We found only a borderline difference in median survival of patients with an initial t-MDS diagnosis compared with patients with an initial t-AML diagnosis...
  10. ncbi request reprint The new World Health Organization classification of myeloid neoplasms: Q&A with James W. Vardiman, MD
    James W Vardiman
    Department of Pathology, University of Chicago, Illinois, USA
    Clin Adv Hematol Oncol 1:18, 21. 2003
  11. ncbi request reprint Myelodysplastic syndromes, chronic myeloproliferative diseases, and myelodysplastic/myeloproliferative diseases
    James W Vardiman
    Department of Pathology, University of Chicago, Chicago, IL 60637, USA
    Semin Diagn Pathol 20:154-79. 2003
    ..It is hoped that when an excellent specimen is available, the guidelines contained in this article may provide the pathologist with assistance in arriving at the most appropriate diagnosis...
  12. doi request reprint The identification and characterisation of novel KIT transcripts in aggressive mast cell malignancies and normal CD34+ cells
    Ozden Ozer
    Section of Hematopathology, Department of Pathology, The University of Chicago, Chicago, IL 60637, USA
    Leuk Lymphoma 49:1567-77. 2008
    ..Our discovery of novel KIT transcripts underscores the importance of analysing entire protein encoding regions when studying genes of interest...
  13. ncbi request reprint Clinical-cytogenetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series
    Sonali M Smith
    Section of Hematology Oncology, Department of Medicine, MC2115, University of Chicago, 5841 S Maryland Avenue, Chicago, IL 60637, USA
    Blood 102:43-52. 2003
    ..0001). Median survival time after diagnosis of t-MDS/t-AML was 8 months; survival at 5 years was less than 10%. These data confirm and extend previous associations between clinical, morphologic, and cytogenetic findings in t-MDS/t-AML...
  14. pmc Distinct patterns of mutations occurring in de novo AML versus AML arising in the setting of severe congenital neutropenia
    Daniel C Link
    Division of Oncology, Department of Medicine, Washington University, St Louis, MO 63110, USA
    Blood 110:1648-55. 2007
    ..These data support the hypothesis that mutations of CSF3R may provide the "activated tyrosine kinase signal" that is thought to be important for leukemogenesis...
  15. ncbi request reprint Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel
    Ayalew Tefferi
    Mayo Clinic, Rochester, MN 55905, USA
    Blood 110:1092-7. 2007
    ....
  16. ncbi request reprint The diagnostic interface between histology and molecular tests in myeloproliferative disorders
    Ayalew Tefferi
    Division of Hematology, Mayo Clinic, Rochester, Minnesota, USA
    Curr Opin Hematol 14:115-22. 2007
    ..This review discusses how this process is unfolding in myeloproliferative disorders...